WO2005016266A3 - Methods for treating cardiovascular disease using a soluble ctla4 molecule - Google Patents

Methods for treating cardiovascular disease using a soluble ctla4 molecule Download PDF

Info

Publication number
WO2005016266A3
WO2005016266A3 PCT/US2004/024840 US2004024840W WO2005016266A3 WO 2005016266 A3 WO2005016266 A3 WO 2005016266A3 US 2004024840 W US2004024840 W US 2004024840W WO 2005016266 A3 WO2005016266 A3 WO 2005016266A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating cardiovascular
soluble ctla4
cardiovascular disease
ctla4 molecule
Prior art date
Application number
PCT/US2004/024840
Other languages
French (fr)
Other versions
WO2005016266A2 (en
Inventor
James Rusnak
Original Assignee
Bristol Myers Squibb Co
James Rusnak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, James Rusnak filed Critical Bristol Myers Squibb Co
Priority to AU2004264901A priority Critical patent/AU2004264901B2/en
Priority to BRPI0413326-9A priority patent/BRPI0413326A/en
Priority to JP2006522651A priority patent/JP2007501243A/en
Priority to MXPA06001225A priority patent/MXPA06001225A/en
Priority to EP04779791A priority patent/EP1670499A4/en
Priority to NZ545314A priority patent/NZ545314A/en
Priority to CA2534474A priority patent/CA2534474C/en
Publication of WO2005016266A2 publication Critical patent/WO2005016266A2/en
Publication of WO2005016266A3 publication Critical patent/WO2005016266A3/en
Priority to NO20060477A priority patent/NO20060477L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
PCT/US2004/024840 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble ctla4 molecule WO2005016266A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2004264901A AU2004264901B2 (en) 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble CTLA4 molecule
BRPI0413326-9A BRPI0413326A (en) 2003-08-04 2004-08-03 methods for treating cardiovascular disease by employing a soluble ctla4 molecule
JP2006522651A JP2007501243A (en) 2003-08-04 2004-08-03 Method for treating cardiovascular disease using soluble CTLA4 molecule
MXPA06001225A MXPA06001225A (en) 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble ctla4 molecule.
EP04779791A EP1670499A4 (en) 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble ctla4 molecule
NZ545314A NZ545314A (en) 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble CTLA4 molecule
CA2534474A CA2534474C (en) 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble ctla4 molecule
NO20060477A NO20060477L (en) 2003-08-04 2006-01-30 Methods for treating cardiovascular diseases using a soluble CTLA4 molecule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49243003P 2003-08-04 2003-08-04
US60/492,430 2003-08-04

Publications (2)

Publication Number Publication Date
WO2005016266A2 WO2005016266A2 (en) 2005-02-24
WO2005016266A3 true WO2005016266A3 (en) 2005-07-07

Family

ID=34193123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024840 WO2005016266A2 (en) 2003-08-04 2004-08-03 Methods for treating cardiovascular disease using a soluble ctla4 molecule

Country Status (15)

Country Link
US (3) US7307064B2 (en)
EP (1) EP1670499A4 (en)
JP (1) JP2007501243A (en)
KR (2) KR20060132541A (en)
CN (1) CN1863546A (en)
AU (2) AU2004264901B2 (en)
BR (1) BRPI0413326A (en)
CA (2) CA2762015A1 (en)
MX (1) MXPA06001225A (en)
NO (1) NO20060477L (en)
NZ (2) NZ573652A (en)
RU (1) RU2353384C2 (en)
SG (1) SG144925A1 (en)
WO (1) WO2005016266A2 (en)
ZA (1) ZA200601031B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DE60225914T2 (en) 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. PROCESS FOR PROTECTING AN ALLOGENIC ISLAND TRANSPLANT WITH SOLUBLE CTLA4 MUTATION MOLECULES
ES2354610T5 (en) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Improved product quality in mammalian cell culture procedures for protein production
MXPA05006523A (en) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Mammalian cell culture processes for protein production.
MXPA06001225A (en) * 2003-08-04 2006-04-11 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule.
PE20080556A1 (en) * 2005-12-20 2008-06-13 Bristol Myers Squibb Co COMPOSITION INCLUDING AN ISOLATED POPULATION OF CTLA4-IG MOLECULES FROM A LIQUID CULTURE MEDIUM AND METHODS FOR OBTAINING THEM
TWI393575B (en) * 2005-12-20 2013-04-21 必治妥美雅史谷比公司 Stable protein formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co METHODS TO PRODUCE A COMPOSITION WITH CTLA4-IG MOLECULES FROM A CROP MEANS
KR101383476B1 (en) * 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 Immunosuppressive polypeptides and nucleic acids
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PT2344540T (en) 2008-10-02 2018-02-02 Aptevo Res & Development Llc Cd86 antagonist multi-target binding proteins
US9738872B2 (en) * 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
US9546112B2 (en) * 2010-03-22 2017-01-17 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
CA2810631A1 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
CN103282047B (en) 2010-09-08 2016-08-24 耶达研究及发展有限公司 Anti-third party's central memory T cell purposes in leukemia/lymphoma treating
CN102109517A (en) * 2010-12-14 2011-06-29 邵棠 Joint detection method of cardio-cerebral-vascular disease (CCVD) biomarkers and diagnostic kit
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR102073901B1 (en) 2011-09-08 2020-02-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CN102786433B (en) * 2012-03-15 2016-09-21 浙江康恩贝制药股份有限公司 A kind of fumaryl aminated compounds extract and its preparation method and application
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CN103175959B (en) * 2013-02-28 2015-10-14 成都创宜生物科技有限公司 A kind of preparation method detecting premature rupture of fetal membranes immune chromatography test paper
DK3003358T3 (en) 2013-06-07 2021-06-21 Allena Pharmaceuticals Inc COMPOSITIONS AND DIALYSIS DEVICES
EP2883883A1 (en) * 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
ES2870991T3 (en) 2015-04-17 2021-10-28 Alpine Immune Sciences Inc Immunomodulatory proteins with adjustable affinities
US11179448B2 (en) 2015-07-16 2021-11-23 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
MX2018005517A (en) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Cd80 extracellular domain polypeptides and their use in cancer treatment.
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
JP2020517913A (en) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス, インコーポレイテッド Method of treatment with CD80 extracellular domain polypeptide
EP4219540A3 (en) 2017-10-10 2023-12-06 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
US20220125880A1 (en) 2019-02-04 2022-04-28 Assistance Publique - Hôpitaux De Paris Method for treating checkpoint inhibitors induced adverse events
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
WO2021055612A1 (en) 2019-09-17 2021-03-25 BIAL-BioTech Investments, Inc. Substituted imidazole carboxamides and their use in the treatment of medical disorders
WO2021055627A1 (en) 2019-09-17 2021-03-25 Bial- Biotech Investments, Inc. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
CN114901652A (en) 2019-09-17 2022-08-12 比亚尔R&D投资股份公司 Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders
CN115484978A (en) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 Methods and compositions for treating cancer using immune cells
WO2022120388A2 (en) 2020-12-04 2022-06-09 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2023112992A1 (en) * 2021-12-16 2023-06-22 レグセル株式会社 Pharmaceutical composition for treating diseases, disorders, or symptoms related to abnormality in immune system
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
US20020182211A1 (en) * 2000-05-26 2002-12-05 Peach Robert J. Soluble CTLA4 mutant molecules and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ES2123001T5 (en) * 1991-06-27 2009-04-16 Bristol-Myers Squibb Company CTL4A RECEIVER, FUSION PROTEINS CONTAINING IT AND ITS USES.
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5420653A (en) * 1992-01-06 1995-05-30 Mumford; Robin B. Method and apparatus for the amelioration of visual stress and dyslexia
CA2133075A1 (en) 1992-04-07 1993-10-14 Craig B. Thompson CD28 Pathway Immunoregulation
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
AU7107794A (en) 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
SG64335A1 (en) * 1993-12-28 1999-04-27 Seiko Epson Corp Ink jet recording head
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
DE19948126A1 (en) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmaceutical agent for the treatment of cachexia and / or cardiogenic shock
WO2001095928A2 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
DE60225914T2 (en) * 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. PROCESS FOR PROTECTING AN ALLOGENIC ISLAND TRANSPLANT WITH SOLUBLE CTLA4 MUTATION MOLECULES
CA2803741A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of psoriasis with human anti-tnf alpha antibody
ES2354610T5 (en) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Improved product quality in mammalian cell culture procedures for protein production
MXPA05006523A (en) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Mammalian cell culture processes for protein production.
MXPA06001225A (en) * 2003-08-04 2006-04-11 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
US20020182211A1 (en) * 2000-05-26 2002-12-05 Peach Robert J. Soluble CTLA4 mutant molecules and uses thereof

Also Published As

Publication number Publication date
US7307064B2 (en) 2007-12-11
US20090068203A1 (en) 2009-03-12
JP2007501243A (en) 2007-01-25
US7671022B2 (en) 2010-03-02
EP1670499A2 (en) 2006-06-21
ZA200601031B (en) 2007-05-30
KR20090087514A (en) 2009-08-17
AU2004264901A1 (en) 2005-02-24
CA2534474A1 (en) 2005-02-24
US20090041790A1 (en) 2009-02-12
AU2009243460A1 (en) 2009-12-24
MXPA06001225A (en) 2006-04-11
RU2006106636A (en) 2006-09-10
AU2004264901B2 (en) 2009-12-10
NZ573652A (en) 2009-11-27
KR20060132541A (en) 2006-12-21
AU2009243460B9 (en) 2012-03-15
NO20060477L (en) 2006-04-04
EP1670499A4 (en) 2009-07-22
CA2762015A1 (en) 2005-02-24
CN1863546A (en) 2006-11-15
RU2353384C2 (en) 2009-04-27
US20050123539A1 (en) 2005-06-09
WO2005016266A2 (en) 2005-02-24
AU2009243460B2 (en) 2012-03-01
BRPI0413326A (en) 2006-10-10
CA2534474C (en) 2014-09-23
SG144925A1 (en) 2008-08-28
NZ545314A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
WO2005016266A3 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2005086775A3 (en) Lumen-exposed molecules and methods for targeted delivery
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2006040129A3 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2006034154A3 (en) Salts of 5-azacytidine
WO2008079246A3 (en) Cd44 antibodies
WO2005100403A3 (en) Antibodies to erythropoietin receptor and uses thereof
WO2008073162A3 (en) Lysine acetylation sites
WO2006124012A3 (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
WO2007094005A3 (en) Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
WO2008013954A3 (en) Tyrosine phosphorylation sites
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2006110588A3 (en) Methods for treating mild cognitive impairment
WO2007022305A3 (en) 2-aminoimidazopyridines for treating neurodegenerative diseases
WO2008054597A3 (en) Tyrosine phosphorylation sites
WO2005001415A3 (en) Optically pure and enriched isomers of chelating ligands and contrast agents
WO2008013934A3 (en) Tyrosine phosphorylation sites
WO2006031782A3 (en) Salvinorin derivatives as opioid receptor ligands
WO2004098524A3 (en) Lipid platinum complexes and methods of use thereof
WO2008036337A3 (en) Predicted phosphorylation sites
WO2008021542A3 (en) Lysine acteylation sites
WO2007000550A3 (en) Novel indoline compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480028960.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001225

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004779791

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2534474

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12006500258

Country of ref document: PH

Ref document number: 06010049

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006/01031

Country of ref document: ZA

Ref document number: 1020067002436

Country of ref document: KR

Ref document number: 200601031

Country of ref document: ZA

Ref document number: 2004264901

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006522651

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 545314

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004264901

Country of ref document: AU

Date of ref document: 20040803

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004264901

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006106636

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004779791

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413326

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067002436

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12008501843

Country of ref document: PH